Microsoft word - sm%20current%20cv%20july2008.doc
Stephen Murray, M.D., Ph.D.
1408 Schodack Landing Road
Chief Medical Officer
January, 2011 - Present
Chief Medical Officer
Clinical Development and Regulatory Affairs
Therapeutic Area Team Leader, Schizophrenia, Bipolar and Cognition Pfizer Global Pharmaceuticals, Inc.
Worldwide Medical Team Leader, Schizophrenia Full Development Team Leader, Ziprasidone Pfizer Global Pharmaceuticals, Inc. Responsibilities: Phases I-IV January, 2004 – December, 2005
Pfizer Pharmaceutics Group, Inc. Responsibilities: Phase IIIB, IV Indications: Schizophrenia, Bipolar Disorder January, 2001 – January, 2004
Global CNS Clinical Research & Development Janssen Research Foundation Responsibilities: Phases I-III Indications: Schizophrenia, Bipolar Disorder August, 1999 – January, 2001
St. Mary’s Hospital, San Francisco, 1994-1998
Post Graduate Education
Nina Ireland Laboratory of Developmental Neurobiology
Department of Psychiatry , University of California, San Francisco
University of California, San Francisco, Department of Psychiatry
Medical University of South Carolina, Medical Scientist Training
University of South Carolina, South Carolina College
American Board of Psychiatry and Neurology, Psychiatry, February 1999
Medical Board of California, Licensed Physician, December 1993
New York State, Licensed Physician, January 2004
Diplomate, National Board of Medical Examiners, July, 1993 Fellowships, Scholarships and Awards
Department of Veterans Affairs, Fellowship in Biological Psychiatry, 1996-1998
National Institutes of Health, Research Training Grant, Sam Barondes, MD,
Principal Investigator, July, 1995 – July, 1996
National Institutes of Health, Research Award for Clinical Trainees, September, 1993 Medical Scientist Training Program, (MUSC), Student Fellowship, 1985-1992 South Carolina Medical Association Auxiliary Medical Student Scholarship, 1989 University of South Carolina Alumni Association Scholarship, 1981-1985
Del Valle, MC, Loebel, AD, Murray, S
, Yang, R, Harrison DJ, Cuffel, BJ.
Change in Framingham risk score in patients with schizophrenia: a post hoc analysis of a randomized, double-blind, 6-week trial of ziprasidone and olanzapine. Prim Care Companion J Clin Psychiatry
, 2006; 8(6):329-33.
Olie, JP, Spina, E, Murray, S
, Yang, R. Ziprasidone and amisulpride effectively
treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. Int Clin Psychopharmacolol
, 2006; 21(3):143-51.
Simpson, GM, Weiden, P, Pigott, T, Murray, S
, Siu, CO, Romano, SJ. Six-
month, blinded multicenter continuation ostudy of ziprasidone versus olanzapine in schizophrenia. Am J Psychiatry
, 2005; 162(8):1535-8.
Whistler, JL, Enquist, J, Marley, A, Fong, J, Gladher, F, Tsuruda, P, Murray, SR
von Zastrow, M. Modulation of postendocytic sorting of G-protein-coupled receptors. Science
, 2002; 297: 615-620.
Mathews, C, Glidden, D, Murray, SR
, Forster,P Hargreaves, W. The effect on
treatment outcomes of assigning patients to ethnically focused inpatient psychiatric units. Psychiatric Services
, 2002; 53(7): 830-835.
Glick, ID, Murray, SR
, Vasudevan, P, Marder, SR, Hu, RJ. Treatment with
atypical antipsychotics: new indications and new populations. Journal of Psychiatric Research
, 2001, 35: 187-191.
, Evans, CJ, von Zastrow, M. Phosphorylation is not required for
dynamin-dependent endocytosis of a truncated mutant opioid receptor. Journal of Biological Chemistry
, 1998, 273(39):24987-91.
Keith, DE, Anton, B, Murray, SR
, Zaki, PA, Lissin, DV, Stewart, PL, Evans CJ,
von Zastrow, M. Mu-opioid receptor internalization: Opiate drugs have differential effects on a conserved endocytic mechanism in vitro and in the mammalian brain. Molecular Pharmacology
, 1998; 53(3):377-384. Chu,
, Lissin, DV, von Zastrow, M. Delta and kappa opioid
receptors are differentially regulated by dynamin-dependent endocytosis when activated by the same alkaloid agonist. Journal of Biological Chemistry
, 1997; 272(43):27124-30. Keith,
, Zaki, PA, Chu, PC, Lissin, DV, Kang, L, Evans, CJ, von
Zastrow, M. Morphine activates opioid receptors without causing their rapid internalization, Journal of Biological Chemistry
, 1996; 271(32):19021-19024.
and Haller, E. Neuroleptic malignant syndrome associated with
risperidone treatment. Psychiatric Services, lett
, 1995; 46(9):951. Chen,
, Chai, KX, Chao, L and Chao, J. Molecular cloning and
characterization of a novel kallikrein transcript in colon and its distribution in human tissues. Brazilian Journal of Medical and Biological Research
, 1994; 27:1829-1838.
and Brewerton, T. Abuse of over-the-counter dextromethorphan: a
report of two cases. The Southern Medical Journal
, 1993; 86(10):1151-1153.
, Chao, J and Chao L. Evolution of the kallikrein gene family.
Agents and Actions Supplements
, 1992; 38(I):26-33.
Chai, KX, Ma, J-X, Murray, SR
, Chao, J and Chao, L. Molecular cloning and
analysis of the rat kallikrein-binding protein gene. Journal of Biological Chemistry
, 1991; 266(24):16029-16036.
, Chao, J and Chao, L. Kallikrein multigene families and the
regulation of their expression. Journal of Cardiovascular Pharmacology
, 1990; 15(Suppl.6):S7-S16.
Wells, DE, Anstrom, JA, Raff, RA, Murray, SR
and Showman, RM. Maternal
stores of alpha-subtype histone mRNAs are not required for normal early development
of sea urchin embryos. Roux's Archives of Developmental Biology
, 1986; 195:252-
Murray, SR. "Analysis of the human kallikrein gene family: evolutionary
considerations." Doctoral dissertation, Medical University of South Carolina, 1990.
Murray, SR. "Alkaline phosphatase in sea urchin embryos." Senior thesis, South
Carolina College, University of South Carolina, 1985.
In the Laboratory Synthesis of Aspirin John Olmsted III Department of Chemistry and Biochemistry, California State University, Fullerton, Fullerton, CA 92834 In recent years, examples from organic chemistry haverecognition, as the reactions modify the periphery of a struc-come to play increasingly prominent roles in the first-yeartural core common to the starting material, intermediate
LES TRAITEMENTS MEDICAMENTEUX DE L’ENDOMETRIOSE GENITALE : RECOMMANDATIONS Recommandation de Bonne Pratique LES TRAITEMENTS MÉDICAMENTEUX DE L’ENDOMÉTRIOSE GÉNITALE (EN DEHORS DE L’ADENOM YOSE) RECOMMANDATIONS Agence Française de Sécurité Sanitaire des Produits de Santé – Décembre 2005 LES TRAITEMENTS MEDICAMENTEUX DE L’ENDOMETRIOSE GENITALE : RECOMMANDATI